Skip to main content

Table 4 An independent set of 44 GBM specimens to examine the effects of nuclear FABP7 and EGFR expression on patient survival

From: Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma

Case # Diagnosis Age Survival (wk) Censor FABP7 Nu EGFR IHC New Category*
17 GBM 54.2 73.2 1 0 0 0
30 GBM 24.3 203.9 1 0 0 0
45 GBM 45.2 67.9 1 0 0 0
46 GBM 26.9 146.7 0 0 0 0
66 GBM 17.5 133.5 0 0 0 0
68 GBM 31.6 146.9 1 0 0 0
81 GBM 51.1 60.6 1 0 0 0
84 GBM 43.6 66.8 0 0 0 0
87 GBM 59.9 43.4 1 0 0 0
91 GBM 46.4 383.0 0 0 0 0
94 GBM 54.0 33.7 1 0 0 0
98 GBM 39.1 48.6 1 0 1 1
99 GBM 56.9 128.1 1 0 1 1
107 GBM 59.1 79.8 1 0 2 1
110 GBM 45.2 35.1 1 0 2 1
148 GBM 59.8 35.1 1 0 2 1
194 GBM 54.8 32.7 1 0 2 1
225 GBM 54.1 94.3 1 0 2 1
243 GBM 50.6 76.8 1 0 2 1
263 GBM 54.7 123.1 1 0 2 1
277 GBM 42.5 25.1 0 0 2 1
284 GBM 47.7 92.3 1 0 2 1
29 GBM 35.3 97.0 1 0 2 1
89 GBM 55.2 45.1 1 1 0 2
273 GBM 42.5 39.0 0 1 0 2
4 GBM 51.0 29.5 1 1 0 2
21 GBM 59.3 32.7 1 1 0 2
32 GBM 58.2 22.1 1 1 0 2
53 GBM 51.2 23.8 1 2 0 2
54 GBM 33.1 32.7 0 2 0 2
58 GBM 37.2 31.1 1 2 0 2
61 GBM 12.8 12.3 0 2 0 2
88 GBM 52.2 93.9 1 2 0 2
100 GBM 45.8 11.3 1 2 0 2
103 GBM 55.1 13.9 1 2 2 3
105 GBM 41.7 46.1 1 2 2 3
106 GBM 43.8 10.5 0 2 2 3
207 GBM 51.3 27.1 1 2 2 3
240 GBM 45.2 13.3 1 2 2 3
247 GBM 58.7 43.3 1 2 2 3
265 GBM 58.8 80.1 1 2 2 3
34 GBM 54.4 36.0 1 1 1 3
38 GBM 23.0 24.1 1 1 2 3
50 GBM 25.0 41.0 1 1 2 3
  1. *Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual positive as "3"